The MDM2 inhibitor idasanutlin, which blocks the MDM2-p53 interaction and hence proteasomal degradation of the latter, reduced tumour growth in an MRT xenograft model via upregulation of p53 [121]. This evidence concerns the gene TP53 and neoplasm.